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In 1985, the serendipitous discovery of fullerene triggered the research of carbon structures into the
world of symmetric nanomaterials. Consequently, Robert F. Curl, Harold W. Kroto and Richard E.
Smalley were awarded the Noble prize in chemistry for their discovery of the buckminsterfullerene
(C60 with a cage-like fused-ring structure). Fullerene, as the first symmetric nanostructure in carbon
nanomaterials family, opened up new perspectives in nanomaterials field leading to discovery and
research on other symmetric carbon nanomaterials like carbon nanotubes and two-dimensional
graphene which put fullerenes in the shade, while fullerene as the most symmetrical molecule in the
world with incredible properties deserves more attention in nanomaterials studies. Buckyball with its
unique structure consisting of sp2 carbons which form a high symmetric cage with different sizes
(C60, C70 and so on); however, the most abundant among them is C60 which possesses 60 carbon atoms.
The combination of unique properties of this molecule extends its applications in divergent areas of
science, especially those related to biomedical engineering. This review aims to be a comprehensive
review with a broad interest to the biomedical engineering community, being a substantial overview of
the most recent advances on fullerenes in biomedical applications that have not been exhaustively and
critically reviewed in the past few years.Introduction
Carbon is one of the most abundant elements in nature and
definitely holds one of the first places in nanomaterials research
field. Entering the carbon-based nanomaterials world was trig-
gered by the discovery of buckminsterfullerene (shortened to
fullerene or buckyball), the third carbon allotrope, after graphite*Corresponding author: Mozafari, M. (mozafari.masoud@gmail.com)
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Richard E. Smalley [1]. Since geodesic domes designed by Buck-
minster Fuller in 1960s provided clues to realize fullerene C60’s
structure, this molecule was named after this American architec-
ture, buckminsterfullerene. After this discovery, in 1990, Wolf-
gang Kra¨tschmer of the Max Planck Institute for Nuclear Physics,
and Donald Huffman of the University of Arizona, with their
students, prospered in producing fullerene in bulky quantitiesnse (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.mattod.2017.03.017













w[2]. Finally, in 1996 Kroto, Smalley and Curl were awarded the
Noble Prize in Chemistry for fullerene discovery.
Nowadays, we know fullerenes exist in nature and interstellar
space [3,4]. In the past, fullerene was Molecule of the Year in 1991,
and has attracted majority of research projects than other scientific
subjects, to the extent that average rate of publications was every
thirteen hours in first few years after its discovery [5].
Nanodiamond which is a significant member in carbon nano-
materials family has been discovered before fullerene in 1963–
1982. Indeed, fullerene could be considered as the first discovery
among symmetric carbon nanostructures [6–8], and its discovery
revealed new perspectives in carbon-based materials that resulted
in research on carbon nanotubes, cylindrical cousin of buckyball,
and rapid developments in advanced materials field.
Although the emergence of 2D carbon nanomaterials, as gra-
phene reported by Geim and Novoselov in 2004, who were
awarded the Noble Prize in 2010, marginalized fullerenes and
moved the majority of the studies towards other carbon nanos-
tructures [9,10], the incredible properties of fullerene could not be
underestimated.
Fullerene, with its unique structure consisting of sp2 carbons,
presents a high symmetric cage with different sizes (C60, C76 and so
on). The most abundant fullerene in the as-synthesized composi-
tion is C60, the molecular structure of which, together with the one
of C70, can be observed in Fig. 1 [11]. C60 consists of 60 carbon
atoms with C5–C5 single bonds which form 12 pentagons and C5–
C6 double bonds which from 20 hexagons [1]. Indeed, each
fullerene with 2n + 20 carbon atoms contains ‘n’ hexagon [12].
As shape, fullerene C60 is like a soccer balls, and Yadaf et al. [13]
have stated that the ratio of fullerene molecule to soccer ball is the
same as the ratio of soccer ball to the earth, where the diameter of
the earth, soccer ball and fullerene molecule are 12.75  106 m,
2.2  101 m and 7.0  1010 m, respectively.
In relation to crystallographic properties of fullerene molecule,
the presence of symmetric elements including 30 twofold axes, 20
threefold axes and 12 fivefold axes has made fullerene the most
symmetrical molecule (as already mentioned) that is controlled by
Golden Mean rule [13,14]. C60, with face centered cubic lattices
(FCC) in solid phase, has a stable structure to the extent that the
destruction of fullerene cage happens at temperatures higher than
10008C. Divergent spectroscopic methods like Raman spectrosco-
py, UV–vis, NMR and FTIR could be deployed to characterizeFIGURE 1
Schematic of fullerene molecules (C60 and C70).fullerene [11]. Moreover fullerene results to be a compatible nano-
material with biomolecules specially which are structured by
Fibonacci sequence and possess Golden Mean properties too
[15]. Among the different characteristics of this molecule, C60
has the ability to produce oxygen species in exposure of visible
light and makes it a suitable candidate for photodynamic therapy
[16]. The interesting behavior of fullerene in solutions presents a
unique solvent–solute interaction in which rigid molecular struc-
ture of fullerene has not been undergone conformational and
solvent-dependent changes [17]. Solubility of fullerenes has been
investigated with discrepant experiments, nevertheless, fullerenes’
solubility is not predictable and there is no reliable theory to
explain fullerenes’ behavior in various solvents [18].
Pristine C60 has very low solubility in water; however, it can
form aggregates in water solutions and make stable colloid solu-
tions which contain both individual fullerene and fullerene clus-
ters [19]. Ruoff et al. showed that fullerene solubility is a function
of several factors such as refractive indices, dielectric constants and
molecular volumes. The dielectric constant of water at room
temperature is approximately 80, which is high, index of fraction
of water at room temperature is 1.33 and its molar volume is 18 ml/
mol and these index fraction and molar volume of water are small
for fullerene solubility [17,20].
The hydrophobic nature of fullerene makes its solubility in
organic (especially aromatic) solvents like toluene, chloroform
and benzene quite high [21,22], while in polar solvents it is very
challenging, and this is critical for biological applications. A
number of methods have been developed in order to boost fuller-
ene solubility in water like preparing two-phase colloidal solu-
tions, synthesizing fullerene derivatives and fullerene polymers
[23,24]. Although hydrophobicity of fullerene provides it with
some degrees of compatibility in biological systems, hydrophilici-
ty of materials in biological environments has greater importance
in comparison with hydrophobicity.
As mentioned above, different strategies have been exploited in
order to promote fullerenes’ behavior in solvents, especially aque-
ous dispersions, which play a crucial role in biological applications
[25–27]. One of them is involved with transferring fullerenes from
an organic solution such as toluene or benzene to an aqueous
phase with ultrasound treatment with following removal of the
organic solvent [21,28]. The mechanism of fullerene dispersal in
aqueous solutions with the aforementioned method could be
explained in two ways: (i) the formation of water shell via H-
bonding and charge transfer between C60 and water molecules
stabilizes fullerene in water [19,29] and (ii) ultrasound treatment
creates a covalent bond between hydroxyls and carbons in fuller-
ene cage, which culminates in fullerenol moieties and consequent
easy fullerene dissolution [19,30]. Other attempts include encap-
sulation in special carriers like cyclodextrins, calixarenes, poly-
vinylpyrrolidone, micelles and liposomes, which give advantages
for biopharmaceutical applications like drug delivery [31–33]. In
addition to the mentioned methods, chemical modification of
fullerene with hydrophilic substance such as amino acids, carbox-
ylic acids, polyhydroxyl groups, or amphiphilic polymers
enhances hydrophilicity of fullerenes in biological systems [34–
36]. Once rendered soluble in biological media, the excellent
properties of buckminsterfullerene make it useful for biomedical
applications including antiviral activity, antioxidant activity as a461
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FIGURE 2
Distribution of various biomedical applications of fullerene.
FIGURE 3
Schematic of fullerene synthesis methods: (a) Huffman–Kra¨tschmer method












eview radical scavenger, encapsulating medically materials like magnetic
metals for theranostic applications and as a drug carrier in scaffolds
[37–39].
In order to investigate divergence of publications regarding the
biomedical applications of fullerene, we searched the publications
within the scientific community using Scopus database (date of
search: 21 November 2016). We used keywords including cancer,
photodynamic therapy, antiviral, anti-bacterial, HIV, DNA, RNA,
toxicity, biosensor, antioxidant, imaging, drug deliver, stem cell.
The papers that have these keywords in their title, abstract and
keywords list have been counted and the results of the distribution
of them in various biomedical applications are demonstrated in
Fig. 2. The number of papers with word ‘toxicity’ is more than
other keywords and it demonstrates the great importance that was
placed to the toxicity of the fullerenes which is a prerequisite for
the biomedical applications of fullerenes.
Now, in the 30th anniversary of C60 discovery, we consider that
is time to review the progress of the fullerene-based research from
its birth until now. In this article, we will review 30 years of
investigations on fullerenes, started in 1985 with a serendipitous
discovery. Although the advent of other carbon nanomaterials like
the carbon nanotubes and the two dimensional graphene put
fullerenes in the shade, this form of carbon, that can be considered
a 0D carbon nanostructure, deserves great attention in nanoma-
terials studies, especially considering that, contrary to the other
cited materials, its structure is perfectly define, the reproducibility
of its functionalization is not an issue and its characterization can
take advantage of both classical and innovative techniques.
Synthesis of C60 fullerene
Huffman–Kra¨tschmer method
Three main methodologies for production of fullerenes have been
utilized, evaporation of carbon, incomplete combustion of ben-
zene in oxygen [40] and microwave method [41]. The first bulky
production of fullerene, which has been done by Kra¨tschmer et al.
[2] in 1990, was based upon evaporation and recondensation of
graphite, its schematic is shown in Fig. 3a. Since a requisite for
fullerene formation is carbon atoms in gaseous phase [2,5], in this
process pure graphite was used as a source of carbon atoms, by
heating graphite in helium atmosphere with 100–200 Torr pres-
sure, a light and condensate soot was produced which contained
fullerene. In order to extract fullerene, the soot was dispersed in
benzene in a Soxhlet extractor and the benzenic solution of
fullerene was percolated from the Soxhlet cartridge in the flask462and so separated by the other components [42]. An alternative
method for the fullerene extraction included the soot heating in
an inert gas or under vacuum followed by sublimation and forma-
tion of fullerene [2,40].
In order to vaporize graphite or other sources of carbon like coal,
techniques such as arc-evaporation [2], pyrolysis [43], radio-fre-
quency-plasma [44] and laser ablation [45] could be exploited.
Although these methods provide higher quantity of fullerene, the
arc process results to be the best-established technique for produc-
tion of carbon soot, and it is more efficient and appropriate for
commercial uses. Regardless of the method used to produce carbon
soot, fullerene must be purified, most of the times by extraction
with organic solvents and, because of limited solubility of fuller-
ene in these solvents, large volumes of solvents are needed to
produce acceptable yield of fullerene [5].
Combustion method
Another technology for producing fullerenes is based upon in-
complete combustion of hydrocarbons in sooting flames [46,47].
In 1987, fullerene ions in flames were found and in 1991 Howard
et al. [48] succeeded in extracting significant yields of fullerenes
from laminar sooting flame of premixed mixture of benzene and
oxygen at low pressure, the schematic of the premixed chamber is
shown in Fig. 3b [48,49]. In this method, flame conditions like
pressure, C/O ratio, residence time and gas velocity in combustion
of benzene influence fullerene amount and composition [31–34].
Among them, pressure is an influential factor and formation of
fullerene could be done at low pressure like the astrophysical
atmosphere at temperatures lower than 1700 K [50]. Furthermore,
combustions methods including laser pyrolysis of vapor hydro-
carbons [46] and laser irradiation of polycyclic aromatic hydro-
carbons (PAHs) [51] have been used to produce fullerene.
Microwave method
In addition to the well-known methods mentioned above, there
are technologies exploiting microwave in order to synthesize
fullerene. In 1995, Ikeda et al. [41] obtained fullerene by using
naphthalene and microwave-induced N2 plasma at atmospheric
pressure in a cylindrical coaxial cavity and they reported this
method as an effective route to fullerene synthesis. Microwave-
induced nitrogen plasma is a noticeable source for excitation and
ionization of molecular species like benzene or naphthalene and,













wmoreover, plasma condition could be easily controlled by adjust-
ment of microwave power [41].
Another use of microwave for production of fullerene has been
investigated recently to transform graphite powder to fullerenes.
The microwave method possesses advantages over conventional
heating methods, providing a homogenous heating of the pre-
cursors. In this study it was found that time and temperature did
not affect the production of fullerene, while the amount of graph-
ite powder and microwave intensity led to higher yield of synthe-
sized fullerene [52].
Fullerene functionalization
The unique physical and chemical features of fullerene make it a
favorable option for biological and material chemistry applica-
tions [39,53,54], however its functionalization is often needed for
such purposes. As previously mentioned, despite fascinating prop-
erties of fullerene C60, one obstacle in exploiting this molecule in
biological applications is its insolubility in water and low solubility
in many organic solvents [26]. The presence of double bonds is the
most effective feature exploited to functionalize fullerene. In fact,
they can be involved in addition reactions, therefore, the outer
sphere of the carbon cage can be modified, and derivatives con-
taining various functional groups can be synthesized [55]. Also,
pristine fullerene contains no hydrogen atom and cannot involve
substitution reactions, however fullerenes are oxidizing agent, in
particular when exposed to UV–visible irradiation can produce
active oxygen forms [56].
Two approaches have been used to modify fullerenes: (a) use of
solubilizing agent to partially mask fullerene surface, and (b)
chemical modification of fullerene via covalent functionalization
[39,57,58]. The first can take advantage of linking polymer chains
to fullerene [59], entrapping this molecule in cyclodextrins or
calixarenes [26,60,61], incorporating into artificial lipid mem-
branes [62,63], inducing co-solvation with polyvinylpyrrolidone
in organic solvents [60]. Numerous functionalization routes have
been used to enhance fullerene hydrophilicity and also extent its
biological and pharmaceutical applications [39]. Alteration of
carbon atoms’ hybridization from sp2 to sp3 is the driving force
for addition to fullerene [61]. Various free-radical reactions, cyclo-
propanation, or cycloaddition reactions such as [1 + 2], [2 + 2],
[3 + 2] and [4 + 2] reactions can covalently conjugate various
molecules to C60 (for an example see Fig. 4) [36]. Due to the
electron deficient nature, fullerene behaves as a 2p electron-defi-
cient dienophiles and 1,3-dipolarophiles, which experience a va-
riety of cycloaddition reactions such as [1 + 2], [4 + 2] (Diels–Alder
reactions), [3 + 2], and [2 + 2]. A large number of fullerene deriva-
tives have been prepared using different types of cycloaddition
reactions [64].FIGURE 4
Example of a [2 + 1] cycloaddition reaction.The latter approach, that is, the chemical modification, is an
advanced and effective method which resulted in a variety of
fullerene derivatives with attached amine (–NH2), hydroxyl (–
OH) and/or carboxyl groups (–COOH) and examples of some of
the so-obtained derivatives are shown in Fig. 5 [26,39].
Among the various fullerene functionalizing routes, Hirsch et al.
[65] succeeded in obtaining great results by attaching carboxylic
groups in dendrimeric mode to the fullerene and promoted its
solubility in water. Filippone et al. [66] also used a covalent
functionalization to link C60 and cyclodextrines, with the synthe-
sis of (permethylated-b-cyclodextrin)–fullerene conjugate in order
to enhance fullerene solubility in water and polar media. Also
fullerenols, which contains hydroxyl group with C60(OH)n formu-
la, present a very good water solubility and have been utilized to
absorb oxygen free radicals and to reduce neuronal tissue damage
[66]. In addition carboxyfullerenes have been exploited in the
treatment of neurodegeneration caused by amyotrophic lateral
sclerosis (ALS) [67,68].
Endohedral fullerenes
The fullerene hollow cage allows to use this carbon nanostructure
as container for various atoms, ions and molecules and the term
‘endohedral’ is used to indicate such fullerene species. Endohedral
metallofullerene is a captivating class of fullerenes which modifies
electric and magnetic properties of fullerene cage and extents
applications of this carbon allotrope in different fields especially
in the realm of biomedicine.
Synthesis of endohedral fullerene
Until now, various methods have been developed for the produc-
tion of endohedral fullerenes in macroscopic scale, similarly to the
fullerene preparation strategies, with the creation of carbon-rich
plasma in atmosphere containing inert gas like He or Ar. These
techniques include vaporization of graphite with arc discharge
[69–71], laser ablation [72–76], radiofrequency furnace [77] and
resistive heating [78], implantation of the atoms through the
carbon cages’ walls via ion bombardment [79–81], high pressure
treatment [82–84] and the last technique is the chemical routes by
opening orifices in the fullerenes [85,86]. Among these methods,
arc discharge is the most favorable for production of endohedral
fullerene [87].
Initially, endohedral metallofullerenes (EMFs) were produced
by laser ablation. In this process, a composite disk containing
graphite and metal oxide is located in a furnace at 12008C [88]. By
irradiation of 532 nm laser onto the composite, EMFs and empty
fullerenes are generated and flow through the tube with inert gas
and then they deposit on the tube wall [73,89]. Nonetheless, this
method is expensive and the production rate is really low, so the
large-scale production of EMFs with this method is limited. Con-
trary to laser ablation technique, the contact arc developed by
Kratschmer and Huffman could be applied for mass production of
EMFs [2,69,71]. A schematic image of its process is shown in Fig. 6.
Inhere, metal/graphite composite rods are used as anode and are
exposed to a temperature above 16008C in order to form metal
carbides in the composite rod for efficient production of EMFs.
Then, composite rods are arced in direct current in the range of
300–500 A and under flowing of He as a cooling gas. In the further
step, the produced soot can be collected [90]. This method is463
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(a) (b) (c)
FIGURE 5
Structures of: (a) polyhydroxylated fullerene; (b) carboxyfullerene; (c) amino acidic fullerene.
FIGURE 6
Schematic view of a Kra¨tschmer–Huffman generator for production of
endohedral metallofullerenes.
FIGURE 7
(a) SEM image of fullerene nano whiskers showing the morphology of the
nanowhiskers [97]; (b) model of one-dimensional fullerene nanowiskers with
body-centered tetragonal crystal structure where a and c are lattice











eviewproficient and cost-effective for production of EMFs [87]. There are
two main obstacles in the extensive research regarding the struc-
tural properties of EMFs. First, the difficulties in separation of EMFs
culminated in the low availability of pure and symmetric single
crystal of endohedral metallofullerenes. Second, because of the
intrinsic features of EMFs, investigation of them with standard
tools faced with numerous limitations [87]. In addition to low
amount of single crystals of endohedral metallofullerenes, X-ray
diffraction investigations of single crystals were impeded rotation-
al disorder of the single crystal of fullerene molecule [87].
Fullerene-based nanomaterials
Self-assembly is a technique which has been used for synthesizing
functional molecules with a variety of nanostructures. Nano-sized
fullerene crystals have intermediate size, between molecules and
bulk materials. Various methods exploited this characteristic in
order to prepare 1D or 2D fullerene-based nanostructure [91].
Self-assembled fullerene nanostructure with disparate shapes
could be synthesized by vapor-driven crystallization, liquid–liquid
interfacial precipitation (LLIP), drop drying process and template
assisted dip drying [92]. Fullerene fine fibers, which contain single-
crystal C60, present diameters ranging from 100 nm to a few
microns and their lengths are hundreds of microns. They are464called C60 nanowhiskers, and represent a 1D fullerene nanostruc-
ture (Fig. 7a) [91,93]. Fullerene nanowhiskers are crystalline thin
fibers and can contain pristine C60, or/and endohedral or/and
functionalized fullerenes [93]. The nanowhiskers could be synthe-
sized by liquid–liquid interfacial precipitation (LLIP) method,
which is the most convenient procedure for preparation of Fuller-
ene nanowhiskers and it was developed by Miyazawa and collea-
gues [94–96]. In this method a solvent, in which fullerene presents
low solubility as ethanol, isopropyl alcohol (IPA) and isobutyl
alcohol, is mixed with a solvent able to properly dissolve C60 as
toluene, m-xylene, benzene, and CCl4. The liquid–liquid interface
Materials Today  Volume 20, Number 8 October 2017 RESEARCH
FIGURE 9
(a) SEM images of fullerene nanosheets; (b) C60/Fc nanosheets [102]; (c) C60
Konpeito-like nano crystals at the interface of IPA and saturated solution of














wbetween these two types solvents is the nucleation site for fuller-
ene crystals [93]. The increase in fullerene solubility in one of the
solvents will enhance the liquid–liquid interfacial pressure which
is required for polymerization of fullerene molecules [97]. Fuller-
ene nanowhiskers with lengths in hundreds microns and diameter
in several nanometers possess a high aspects ratio and also a
Young’s modulus higher than pristine C60 [97]. The schematic
model of a body-centered tetragonal crystal fullerene nanowhis-
kers and its growth direction is shown in Fig. 7b.
In order to improve the characteristics of fullerene nanowhis-
kers and prepare FW/PAni hybrid material, polyaniline emeraldine
base dissolved in N-methyl-2-pyrrolidone (PAni/NMP) was added
to fullerene nanowhiskers by direct-mixing technique. Despite
fullerene nanowhiskers, this hybrid material has a tubular struc-
ture with a pleated surface morphology and consequently has a
higher aspect ratio. The possible mechanism for the formation of
this tubular structure (Fig. 8) is charge-transfer (CT) complex
between the electron-rich polyaniline to electron-deficient fuller-
ene nanowhiskers [98]. In another study, C60 nanowhiskers have
been prepared by LLIP method and vortex-flow-induced align-
ment method has been used for alignment of C60 nanowhiskers. In
this method, mechanical stirring of the medium induces a vortex
flow which aligns fullerene nano whiskers [99]. The aligned
C60NWs on a glass substrate were used as a scaffold for the culture
of human osteoblast MG63 cells. The results of study demonstrat-
ed that cell growth orientation was compatible with axis of
C60NWs and these nanowhiskers were a significant substrate for
adherence and growth of MG63 cells [99].
In addition to fullerene nanowhiskers, recently, fullerene cylin-
drical nanotubes with improved semiconducting and electronic
properties were synthesized via LLIP method. In this procedure
m-xylene and TBA (tetra butyl alcoholic) were used as a saturating
solvent and precipitation agent respectively [100]. In 2007, Sathish
et al. [101] synthesized a flexible, porous and transparent fullerene
hexagonal thin crystalline nanosheets via LLIP method, using
alcohol and CCl4. In this technique, the number of carbon atoms
and the polarity of alcohols influence the particle size of the
supramolecular structure, and high polarity alcohols culminate
in the formation of uniform hexagonal nanosheets, the SEM image
of which is shown in Fig. 9a. However, despite these indications, it
is really hard to obtain a nanostructure with a certain morphologyFIGURE 8
The possible mechanism for the intermolecular interaction between
fullerene nanowhiskers and imine group of PAni.in self-assembly of fullerene because of the presence of many
influential factors [101].
A hybrid hexagonal nanosheet containing C60 and ferrocene
has been prepared via LLIP method. The SEM images of these
nanosheets can be observed in Fig. 9b [102]. The presence of high
charge-transfer (CT) band between fullerene and ferrocene
demonstrates that donor–acceptor interaction exists in the
nanosheets and encourages the formation of C60/Fc nanosheets
[102]. Recently, pressure induced transformation of ferrocene-
doped C60 nanosheets was investigated by in situ Raman spectros-
copy in order to examine their controlled polymerization and
form new planar polymers. With increasing the pressure, orienta-
tion and polymerization of C60 layers happened. The presence of
light irradiation in this polymerization process makes it a more
controlled process and increases the formation of new layers [103].
In 2015, Shrestha et al. [106] reported the synthesis of a assemble
fullerene nanocrystal at liquid–liquid interface of C60 solution in
butylbenzene and IPA. Low solubility of C60 in IPA and slow
diffusion of IPA to fullerene promotes the nucleation of small
fullerene clusters and further growth of crystals in hexagonal
bipyramid and flower-like shape at liquid–liquid interface [106].
Later, the same group investigated the effect of natural nonionic
surfactants, diglycerol monomyristate (C14G12) and diglycerol
monolaurate (C12G2) on crystallization of C60 and the morphology
of fullerene crystals [104], based on their report, the applied
surfactants caused to a morphological transition in fullerene crys-
tals from a 1D faceted rod to a unique zero dimensional nano-
structure called ‘konpeito-like’ fullerene crystals (Fig. 9c). While in
the absence of surfactants the ultimate morphology was the one
dimensional nanorod with hexagonal close-pack structure [104].
One of the most recent fullerene crystal morphologies is fuller-
ene flower which has been prepared via solution-phase crystalli-
zation of fullerene molecules. The presence of mesitylene as a good
solvent, ethanol as a poor solvent and C60 and C70molecules as the
solute and the different between C60 and C70 solubility as the main
factor for occurrence of a two-step crystallization resulted in a
unique nucleation process and formation of the flower-shaped465
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FIGURE 11











eviewcrystals [105]. By controlling the crystallization procedure and
changing effective factors, different fullerene flowers can be
obtained. The SEM image of fullerene flower crystals is shown
in Fig. 9d [105].
Another group of fullerene nanomaterials are polymer/fullerene
nanocomposites which can present novel physico-chemical prop-
erties. Numerous polymers such as polystyrene (PS) and polyeth-
ylene glycol have been used as matrices for these nanocomposites
[107]. Li et al. [108] in 2000 produced a nanocomposite including
fullerene and polycaprolactone (PC) and improved electron
accepting characteristics of the nanocomposites. They integrated
fullerene derivative 1,2-(10,10,20,20-tetracyanomethanoxymetha-
no)C60 (TCNEO-C60) into polycarbonate (PC), the structure of
which is shown in Fig. 10a, moreover they covalently linked N-
methyl-pyrrolidino[60]fullerene to polycarbonate chain (MPYLD-
C60-PC, Fig. 10b).
In 2007, a nanocomposite containing fullerene and polystyrene-
polyisoprene-polystyrene (SIS) and polystyrene-polybutadiene-
polystyrene (SBS) copolymers was synthesized (Fig. 11) [109] and
their characteristics were investigated, finding that with the in-
crease in fullerene content, the nano-tack adhesive forces decrease
and the bulk forces also showed results similar to nanoforces.
Another nanocomposite containing fullerene was synthesized
by Ag nanoparticles embedded in C60 matrix via thermal co-
deposition and the effect of temperature and nanoparticles per-
cent in silver-fullerene nanocomposites was examined [110].
Li et al. [111] developed a polymer/fullerene nanostructure with
defined morphology and polymer fiber orientation via a novel
technique based on no-covalent interactions between copolymer
and fullerene derivative. Another group of fullerene nanocompo-
sites are gel-nanocomposites, in which fullerenes are embedded in
the fibrillary gel networks. Incorporation of fullerene boosts the
stability of the gels and their melting point. One example of these
composites is fullerene-PEG gel, which has acceptable thermal
stability and solubility in solvents like methanol, water and THF
[112].
Another group of polymer/fullerene nanostructure is polymer/
fullerene core–shell composite nanofibers (NFs) which can be
applied in solar cells and can enhance the performance of polymer
based solar cells [113]. A novel composite containing conjugated
polymer (poly[2-methoxy-5-(2-ethylhexyl-oxy)-p-phenyleneviny-
lene], MEH-PPV) nanoparticles and fullerene phenyl-C61-butyric
acid methyl ester (PCBM) has been developed for applications in
photodynamic therapy (PDT) in which MEH-PPV/PCBM nanopar-
ticles generate ROS (reactive oxygen species) and exert toxicity(a) (b)
FIGURE 10
Polycarbonate containing fullerene derivatives.
466towards cancerous cells [114]. Conjugation of glycol chitosan (GC)
grafted with 2,3-dimethylmaleic acid (DMA) and C60 (GC-g-DMA-
g-C60) is a self-assembled polysaccharide nanogel containing hy-
drophobic (C60) and hydrophilic (GC and DMA) parts that can be
used as a photosensitizer prodrug in PDT [115].
Fullerene hybrid macromolecular structures were synthesized
by aggregation of C60 and terpolymer colloids in isopropyl alcohol
and the mixture of isopropyl alcohol–water. The results demon-
strated that fullerene macromolecular hybrid nanostructures in
isopropyl alcohol were spherical structure with uneven surface,
while in isopropyl alcohol–water mixture clusters of crystalline
nature of fullerene were observed [116]. Recently, a group reported
the preparation of a nanostructure containing fullerene C60 and
carbon composite film via thermal sublimation of in a vacuum of
C60 powder and then the films were deposited onto substrate
materials [117].
The development of more fullerene based nanostructures pro-
vides the opportunities for enhancement of fullerene applications
in various fields like biomedical science and can make fullerene a
more biocompatible and applicable material.
Fullerene containing polymers (polyfullerenes)
Since immediately after the fullerene discovery, fullerene-contain-
ing polymer emerged in materials world being able to associate
extensive and favorable properties of polymers with exceptional
characteristics of fullerenes [118]. Therefore, many efforts allocat-
ed to the synthesis of fullerene-containing polymers or polyfuller-
enes and a large number of publications reviewed those materials.
Polyfullerenes can be classified into certain groups including all-
C60 polymers, cross-linked polymers, organometallic polymers,
C60 dendrimers, end-capped polymers, star shaped polymers, main
chain polymers, side chain polymers and supramolecular poly-
mers [119]. All-C60 polymers also named ‘intrinsic polymers’
can be synthesized via covalent linkage of fullerene units [120].
Organometallic fullerenes can be considered as a kind of all-C60
polymers which contain a metal or element in their structures
[121]. The most favorable properties were attained via palladium
copolymerization [122]. Cross-linked polymers are a group of poly-
fullerenes, which can be synthesized by random reactions with
assistance of C60. Preparation of these cross-linked C60-containing
polymers can be performed by reaction of polymers with C60













wrandomly and in three dimensions [123]. Another class of fullerene-
containing polymers entitled fullerene dendrimers have a regular
branches and at least one fullerene molecule. Fullerene molecules
can be located at the center, at the surface or in the connection
points of the dendrimer [124,125].
The end-capped polymers are considered as a fascinating group
of polyfullerenes, which possess one or two fullerene molecules
placed on the end of polymer backbone and alter its properties.
Fullerene units can be added after the polymer synthesis or,
otherwise the growth of the polymer chain can started from the
fullerene molecule itself [119]. Star-shaped polymers containing a
fullerene unit present from two to twelve long, flexible chains with
a topology similar to sea-stars. These polyfullerenes can be pre-
pared with two approaches: (a) polymer chains can be linked to
fullerene unit, or (b) polymer chains can be grown from the surface
of fullerene unit [126,127].
Another class of C60-containing polymers is the one in which
fullerene units are placed in the backbone of a polymer and formed
a structure similar to a necklace. This polyfullerene can be synthe-
sized by direct reaction of difunctionalized monomers and fuller-
ene cage and also by polycondensation between a fullerene
bisadduct and difunctionalized monomers [128,129]. The most
studied group of C60-containing polymers is side-chain polymers.
These polymers can be prepared in two ways, by direct reaction of
fullerene units with preformed polymers or by functionalization of
fullerene in order to be able to copolymerization with other
monomers [130,131].
The last class of C60-polymers is represented by supramolecular
polymers prepared by Dai et al. [132] in 1999. According to the
synthetic method, supramolecular fullerenes are divided into four
types, (a) interaction between fullerene and functionalized poly-
mers; (b) fullerene derivative self-assembly; (c) multifunctionali-
zation of C60 and complementary polymeric backbones; and (d)
supplementary interactions between pristine fullerene and ditopic
concave guests.
Toxicity and biocompatibility evaluation of fullerenes
Since pristine and derivatized C60 can access to intracellular space
and accumulate into cell membrane and cytoplasm, they might be
a threat for cell functioning and integrity [133–139]. Physiochem-
ical properties, ROS-related behavior and toxicity of fullerene can
generate different results depending on the techniques employed
for the solubilization of pristine C60, including mechanical pro-
cessing, long term stirring in water, and chemical modifications
that can change the general properties of pristine fullerene [140].
In vitro toxicity of pristine and derivatized fullerene
The toxic effects of fullerene colloid prepared with tetrahydrofu-
ran (THF/nC60) on different mammalian cells have been proven in
a number of studies, which demonstrated ROS production, mi-
tochondrial depolarization, and lipid peroxidation resulting to
necrotic cell death [141–143]. One investigation to determine
how THF affects fullerene toxicity in vitro has been done by
Kovochich et al. in 2009 [144]. The authors found that, in mouse
macrophage cell line, the supernatant of THF/nC60 induces
toxicity rather fullerene aggregates because of the presence of
THF byproducts including g-butyrolactone and formic acid. In
fact, these byproducts cause intracellular Ca2+ release, Ca2+increase in mitochondria and their perturbation. Therefore, the
toxicity of THF/nC60 seems to be related to the method used for
fullerene preparation rather than to the intrinsic properties of
pristine fullerene [142–145]. Another study also showed that THF
peroxide is the main factor in oxidative reactivity of THF/nC60
and also this THF derivative plays a significant role in antibacterial
activity of THF/nC60 towards Escherichia coli [146]. In further
studies, it has been confirmed that neither fullerene nor THF
are responsible for toxicity, and indeed THF byproducts, as
g-butyrolactone and THF hydroperoxide, induced toxicity, so
extra washing steps to remove these byproducts led to absence
of toxicity of THF/nC60 in D. magna and A549 lung cells [147].
Further studies showed that preparation of C60 nanoparticles
obtained by solvent exchange using ethanol or toluene instead
of THF, as well as water-stirred C60 suspensions did not cause cell
damage, these finding favored the statement mentioned above
[143,148]. Markovic et al. [140] in 2008 prepared aqu/nC60 via
long term stirring in water, which had low fullerene concentra-
tion and yielded large aggregates formation. The aqu/nC60, made
by sonication, willingly produced singlet oxygen upon illumina-
tion [149], although according to other studies it was not photo-
active [150]. In ambient light situations, aqu/nC60 did not
produce reactive oxygen species and showed only marginal
ROS-independent cytotoxicity in diverse mammalian cells
[143]. It seems that the fullerene functionalization degree can
affect its tendency to form aggregate and monofunctionalized
molecules have more tendency to be aggregated that polyfunc-
tionalized fullerenes, which is more stable in solution [151].
Commonly, there is a belief that derivatization of fullerene can
induce considerable decrease in toxicity for the functionalized
fullerenes. Therefore, highly soluble fullerenes have less cytotoxic
activity since the increase in the number of functional groups
covalently attached reduces the ROS-generating capacity in full-
erenes [141,152]. Polyhydroxylated fullerenes (named fullerols or
fullerenols), when irradiated with UV and visible light, produce
singlet oxygen, although fullerenols produce less ROS than poly-
mer coated fullerenes, they induce photoxidative stress in human
cells [153,154]. However, at sub-cytotoxic concentration fuller-
enols are able to scavenge hydroxyl radicals [155]. Similarly to
fullerenols, carboxyfullerenes are antioxidative/cytoprotective
agents [156] that, under light irradiation, exhibit cytotoxicity.
As mentioned, the ability of fullerene to penetrate cell mem-
branes extensively influences its toxicity: cationic fullerene deri-
vatives that can easily enter cells are more toxic than neutral and
anionic fullerene derivatives [157]. Parental administration of
fullerenes in diagnostic and therapeutic applications, pulmonary
exposure and inhalation of fullerene nanoparticles may lead to
cardiovascular adverse effects, therefore, a number of studies
evaluated fullerene cardiovascular toxicity [158,159]. While C60
preparations obtained by sonication elicited platelet aggregation
in a lower extent than other carbon nanoparticles, not developing
thrombosis, the organic solvent-prepared C60 was found to adhere
to platelets, which may result in thrombosis [68,160].
As previously mentioned, the water-stirred C60 and fullerenols
were found to induce intracellular Ca2+ increase and cause arrest
G1 cell cycle phase in human umbilical endothelial cells, although
in the case of water-stirred C60 no cell death was observed,
while fullerenols cause apoptotic cell death, which may encourage467











eviewcoronary artery diseases and atherosclerosis [159]. In another
study it was shown that fullerenols caused accumulation of poly-
ubiquitinated proteins and autophagy, leading to a decrease in cell
density [161]. In contrast with other fullerene nanoparticles and
derivatives, hexasulfobutyl-C60 is able to inhibit low-density lipo-
protein (LDL) from oxidation, so it can be effective in atheroscle-
rosis prevention [162].
In addition to cardiovascular toxicity, the blood compatibility
of fullerene in vitro has been investigated in a number of studies.
THF/C60 causes oxidative stress mediated lysis of erythrocyte cells
associated with shrinkage and loss of their normal shape, while no
intentional photoirradiation was applied [163]. When fullerenes
enter the blood stream they will translocate to liver, therefore
investigation of toxic effects of fullerenes on liver seems to be
important. g-Cyclodextrin/C60 upon photosensitization triggers
singlet oxygen-dependent oxidative stress in rat liver microsome,
inducing protein oxidation and lipid peroxidation [164]. The
results obtained using polyhydroxylated fullerense were similar
to g-cyclodextrin/C60 [165].
Further studies showed toxic effects of C60(OH)24 under ambi-
ent light on rat hepatocytes which induced lipid peroxidation and
depletion of intracellular ATP, leading to cell death, while
C60(OH)12 exhibited less toxic effects. These results demonstrated
that the toxicity effects of fullerenols are dependent on the num-
ber of hydroxyl groups present on the fullerene carbon cage, and
probably to their solubility too [166].
Another cell type which has been tested for THF/C60 toxicity are
canine kidney cells [167], and also mouse renal epithelial cells were
used to determine some toxicity of sonicated C60, which decreases
the transepithelial electrical resistance, an indicator of epithelial
barrier function [168]. Polyhydroxylated fullerene caused cyto-
skeleton disruption, mitochondrial dysfunction followed by ATP
depletion [169]. The applications of fullerenes as drug carriers in
order to bypass blood ocular barriers nudge researchers towards
assessment of ocular toxicity of fullerene and its derivatives. Upon
UV irradiation g-cyclodextrin/C60 inducing oxygen-mediated pro-
tein peroxidation which led to apoptotic cell death, while in the
dark or ambient light no toxic effect was observed [170]. The more
aggregated g-cyclodextrin/C60, the less singlet oxygen production,
therefore fully aggregated fullerene showed no toxicity effect on
lens cells. In investigation of fullerenol toxicity, it has been
observed that lower fullerenol concentrations caused oxidative
damage to human lens epithelial cells under UV and visible light
irradiation, while higher concentrations showed toxicity even in
the dark [171]. Another study reported that the toxic effect of
fullerenol on retinal pigment epithelial cells was similar to its
toxicity to human lens epithelial cells [172], indicating that the
use of fullerenols in ocular application, especially in the presence
of sunlight, may result in lens or/and retinal damage [173].
Solvent exchange prepared THF/C60 nanoparticles and also
polyvinyl pyrrolidone/C60 complexes can be immediately inter-
nalized by human keratinocytes and then accumulated in cyto-
plasm near the nucleus [174,175]. It has been shown that THF/C60
nanoparticles decreased the growth of human keratinocytes and
under the light its effect increased somewhat [176]. However,
further studies reported the toxic effect of THF/C60 nanoparticles
on human keratinocytes and also human dermal fibroblasts
[141,143].468The complexes of C60 with g-cyclodextrin, sodium dodecyl
sulfate, or polyvinyl pyrrolidone prepared by mechanochemical
approach have no cytotoxicity in vitro [143]. In addition they can
reduce ROS generation, melanin production in human keratino-
cytes and melanocytes under UV irradiation [175,177,178]; this
characteristic makes them applicable in skincare products [179],
though, g-cyclodextrin/C60 under UVA irradiation caused oxida-
tive stress in keratinocytes [180]. In contrast reports related to
cytotoxic evaluation of polyhydroxylated fullerene, it has been
found that C60(OH)32, unlike C60(OH)24 and C60(OH)20, in the
absence of light killed human keratinocytes [181], while other
studies showed that, in human keratinocytes, polyhydroxylated
fullerenes blocked DNA damage and oxidative stress induced by
UV irradiation, so the increase of hydroxyl groups elevated the
cytoprotective activity [178,182].
The reported results demonstrated that both antioxidant activi-
ty and toxicity in the dark rise with the increase in functionaliza-
tion groups attached to fullerene cage, even though, in general,
the definitive effect probably depends on the concentration [173].
Polymer coated fullerenes, in the absence of overt light irradiation,
exhibited no toxicity towards neuronal cell lines [183,184]. The
carboxylated fullerene and hydroxylated fullerene also showed no
toxicity to neural cell lines; however, they decreased the viability
of primary mouse neurons [185].
Recently, an investigation has been accomplished in order to
study the cytotoxicity of two type fullerene solutions on Chinese-
hamster V-79 cells [186]. Two fullerene solutions, one prepared via
solvent exchange method and the other prepared via N-methyl-
pyrrolidone (NMP), in which cluster size is smaller, were prepared
and tested, and in both cases no toxicity was reported in in vitro
tests, demonstrating that N-methylpyrrolidone can be exploited as
solvent in preparing aqueous fullerene solutions [186].
In vivo toxicity of pristine fullerene and derivatized fullerene
Since nanoparticles are able to enter systemic circulation and
exhibit systemic and local toxicity, in vivo evaluation of their
toxicity seems to be significant. Moreover, in vivo tests can dem-
onstrate fullerene toxicity more accurately than in vitro, as this
approach simulates the body environment in more satisfactory
way. The first in vivo study was accomplished in 1996 by injecting
an aqueous suspension of micronized C60 to rodents. In these
experiments, C60 demonstrated to be no deadly, and did not show
acute or sub-acute toxicity to this animal species [187,188].
Fullerenes are able to localize in lipid-rich regions like cell
membranes based on in vitro experiments, and they are redox
active. Additionally, as fullerene can form colloidal aqueous
solution, the oxidative damage caused by fullerene has been
studied in aquatic species, as bass [189]. The results of this study
have shown that, despite change in protein oxidation in any
tissue, changes were observed in lipid peroxidation, in gill and
liver lipid peroxidation, with their decrease, while, in contrast,
brain showed a trend of increased lipid peroxidation. These
differences might be attributed to superior antioxidant defenses
of gill and liver with respect to brain tissues, or fullerenes might
reach the brain before the dissociation of the colloids. Although
this selective localization of fullerenes in cell membrane is fasci-
nating, a balance between advantageous therapeutic and poten-
tial toxic effects can be avoided by coating the fullerenes. Another













wstudy investigated the effect of the THF of entrapped into fuller-
ene aggregates on their toxicity in larval zebrafish [190]. THF have
been used to prepare aqueous C60 aggregates [25], therefore it is
possible that the ascribed toxicity of fullerene aggregates [189] is a
result of the presence of THF in the preparation [190]. The results
demonstrated that THF-C60 and THF-water induced change in
gene expression and survival of zebrafish larvae, while C60-water
had no effect on fish mortality. Although GC–MS did not detect
THF in water sample, byproducts generated from THF treatment,
as the already mentioned g-butyrolactone, seem to be responsible
for the toxic effects [190]. Also the changes in gene expressions
seem to be related to THF and/or its degradation products in fact
C60–water treatment did not induce gene expression changes in
zebrafish, although longer exposure to C60might lead to different
result [190].
Further studies have been performed on the animal exposure to
atmosphere containing fullerene, in order to investigate the effects
of fullerene existing in urban atmospheres. In mice treated by
intratracheal instillation of pure sonicated C60, fullerenes aggre-
gated have been found in alveolar and capillary lumen and also in
pulmonary lymph nodes after exposure [191]. Though no lung
inflammation or histopathological abnormalities were observed,
the presence of fullerene at the air–blood barriers, 5 min after
exposure, suggests that inhalation of fullerene resulted in rapid
translocation of C60 nanoparticles through systemic blood circu-
lation followed by spreading in diverse tissues in the body. In 2009
Fujia et al. exposed rats to inhalation of surfactant (Tween 80)-
dissolved pristine C60 [192]. After 4 weeks, fullerene particles have
been seen in alveolar macrophages; however, no lung tissue ab-
normality has been observed. In other studies, intratracheal instil-
lation of fullerene at high dose (3 mg/kg) significantly increased
the neutrophil-rich inflammation areas up to 1 week after the
administration and also caused a transient increase in the number
of neutrophils in bronchoalveolar fluid [193,194].
According to these results, C60 nanoparticles induce only tran-
sient lung inflammation and no pathologic changes in lung and
also other tissues. Sayes et al., in 2007, observed no increase in
lactate dehydrogenase, alkaline phosphatase and protein values in
bronchoalveolar fluid up to 3 month after the rat intratracheal
instillation of THF/C60 prepared by solvent exchange [195].
According to the results reported by various studies investigating
pulmonary toxicity of pristine and functionalized (hydroxylated)
fullerene, their instillation/inhalation can cause transient inflam-
mation in rats and mice, though continuous inflammation fol-
lowed by tissue damage was observed at high doses [173]. After
intraperitoneal injection of Tween-solubilized C60 (500 mg/kg),
fullerene accumulated in liver, especially in Kupffer cells and rarely
in hepatic stellate cells and hepatocytes, and no parenchymal cell
damage, inflammation or fibrosis were observed with microscopic
examination. In addition, C60 aqueous solution preserved liver
from ROS mediated toxicity of CCl4 [196]. In another study in rats
performed with THF/nC60, the injected fullerene accumulated in
liver, heart, kidney, spleen, lung, intestine, and muscle and bone
tissues. The dose of 0.25 mg/kg of nC60 was not toxic and no
symptoms were observed after two weeks of injections; this finding
was in contrast with in vitro cytotoxicity of THF/nC60 on melano-
ma cells [197]. Administration of polyalkylsulfonated C60 to rats
caused diffuse necrosis of tubular epithelium in kidneys, moreoversome pigment-laden macrophages were observed in spleen, liver
and thymus [198].
Shinohara et al. examined genotoxicity of fullerene by in vitro
and in vivo experiments [199]. They synthesized C60 nanoparticle
suspensions in order to test chromosomal aberration and bacterial
reverse mutation under light irradiation and in dark condition.
Eventually, they concluded that C60 nanoparticle suspensions do
not have genotoxicity neither in the dark nor under light irradia-
tion [199].
A study on fullerene toxicity was performed by Yamago et al.
[200]: by a single intra-peritoneal injection of a water-soluble
methanofullerene (0.5 g/kg of bodyweight), the mice survived
for 1 week. After single intraperitoneal injection of polyhydroxy-
lated C60 to mice (1.2 g/kg), the activity of cytochrome P450-
dependent liver monooxygenase was reduced by the inhibition
of the enzyme catalytic activity. Lower doses of fullerenol injected
intraperitoneal did not influence blood cells in rats; however,
antioxidative capacity of erythrocytes was reduced [201]. By using
lower dose of fullerenol (50 mg/kg), toxic effects completely dis-
appeared [202,203].
Through intravenous injection to rats, THF/nC60 was delivered
all over the body with a high rate of uptake for liver and spleen
[204]. After injection of fullerene aqueous suspension, the mole-
cule rapidly disappeared from circulation and accumulated in the
liver and it was also observed in muscle, lung and spleen, but not in
the brain [176].
In order to evaluate fullerenol as a photodynamic therapy
agent, it has been injected to mouse and, similar to pristine
C60, it was rapidly cleared from circulation and accumulated in
liver, lung, and spleen. Moreover, the results demonstrated that
fullerenol uptake by tumor cells was higher than normal tissue and
so it can be used as photosensitizer in photodynamic therapy of
some types of tumors [205].
A fullerene ammonium salt is also rapidly cleared from circula-
tion; however, its rate is lower than pristine C60. Most of it
accumulated in the liver and the rest in lung, muscle, and skin.
Similarly to pristine C60, it did not reach the brain [176]. The result
of intravenous injection of polyalkylsulfonated C60 (100 mg/kg)
was similar to its intraperitoneal injection and it caused phagoly-
sosomal nephropathy in rats [198].
In addition to systemic administration of fullerene, a number of
studies investigated oral administration of fullerene. A single dose
of (Tween 80)-solubilized C60 (2 g/kg) has orally administered to
rats and no sign of toxicity or abnormalities in any tissue was
observed [206]. In another investigation, oral administration of
C60, dissolved in olive oil, not only does not induce chronic
toxicity, but also doubles the lifespan of rats [207]. In contrast
with these findings, an orally administrated lower dose of pristine
C60 (0.64 mg/kg) in corn oil caused DNA damage in liver and lungs
[208]. From these studies it emerged that the gastrointestinal
adsorption of fullerene and its consequent toxicity is low; howev-
er, in a number of experiments oxidative damage of DNA mediated
by pristine C60 has been reported and this deserves substantial
consideration [173].
Also dermal toxicity of fullerene deserves special attention due
to the cosmetic application of fullerene relating to its antioxidant
activity [173]. Xia et al. [148] in 2010 revealed that penetration of
C60 on pig skin is depending on fullerene vehicle. For example,469











eviewpenetration of chloroform was higher than toluene or cyclohex-
ane, while C60 in mineral oil did not penetrate skin. Investigation
of C60 in propylene glycol in rabbits, pigs and humans demon-
strated no skin irritation or skin reaction [209]. In addition,
polyvinyl pyrrolidone/C60 showed no toxicity in under UV irradi-
ation [210].
Biomedical applications of fullerenes
Antioxidant activity and radical scavenging
Free radicals are produced by normal cellular metabolism as well as
abnormal reactions, encouraged by some disorders. They can
trigger tissue abnormalities along with toxicities and disease pro-
cesses [211], damaging biological molecules like proteins, lipids,
and DNA. This leads to cell damage and, in some cases, to diseases
such as cancer and atherosclerosis [212,213].
One of the main characteristics of C60 is its exceptional free
radical scavenging ability, which makes it favorable ‘free radical
sponge’ in order to protect biological systems against cell damage
and tissue abnormalities [37,38,213,214]. The presence of several
double bonds in fullerene cage makes it able to react with free
radicals [38,215].
Fullerenes, as the most efficient scavenger, can react with free
radical species like superoxide (O2
), and hydroxyl radicals (OH)
and hydrogen peroxide (H2O2) without being consumed; more-
over they can localize within the cells and inhibits free radicals
production. On the other hand, based upon reported studies, it
can be hypothesized that radical scavenging capability of full-
erenes may not be entirely attributed to fullerene cage itself, but
also it can related to functional groups attached to carbon cage,
therefore, free radical deactivating capacity of various fullerenes is
different [140,216]. Because of its insolubility in water, derivatized
fullerenes are more favorable for radical scavenging; moreover
derivatized fullerene can interact with cellular and subcellular
environment more efficiently [140,217]. Wang et al. evaluated
antioxidant activity of C60, of three of its derivatives and of
vitamin E determining the inhibition of lipid peroxidation
[218]. They reported that fullerene derivative efficiently can pre-
vent peroxidation and membrane breakdown triggered by free
radicals, and liposoluble fullerene derivative was more effective in
inhibiting lipid peroxidation than vitamin E, which is a natural
antioxidant. Their results also showed that both fullerene deriva-
tives, liposoluble and water-soluble, can potentially be used as
antioxidant derivatives. This property has been investigated also
for other water-soluble fullerene derivatives, such as C60(OH)n,
carboxyfullerenes, C60(ONO2)72, and hexa(sulfobutyl)fullerenes,
finding good radical scavenging abilities [67,68,219–223].
Derivatization of fullerenes with polar groups like polyhydroxy-
lated fullerenes and tris(malonic)acid-C60 (TMA-C60) makes them
able enter mitochondria, where free radicals are generated and also
TMA-C60 showed strong neuroprotection in several cell culture
models of neurological diseases like Parkinson’s [33,133].
Assessment of radical scavenging properties of aqueous fuller-
ene suspension have been studied by Gharbi et al. [196] who
demonstrated the prevention of free radical related damage in
the liver. The antioxidant properties of dendrofullerene and TMA-
C60 derivatives have been investigated [224], together with amino
acid derivatives of fullerene. For the latter case, fullerene bearing
seven b-alanine demonstrated antioxidant properties against470hydrogen peroxide and prevented induced apoptotic cell death,
since alanine-fullerene impeded ROS accumulation in extra- and
intracellular environment. The a-alanine fullerene derivatives also
showed efficient radical scavenging capability against superoxide
and hydroxyl radicals [215,225]. Also another amino acidic fuller-
ene derivative bearing five cysteines inhibits apoptosis induced by
hydroxyl and superoxide free radicals [226].
Fulleropyrrolidines bearing one or two 3,5-di-tert-butyl-4-
hydroxyphenyl units, reported by Enes et al. [227], have also
confirmed the antioxidant properties. Lin et al. [228] investigated
the antioxidant activity of carboxyfullerene by in vitro study and
the iron-induced lipid peroxidation and auto-oxidation of brain
homogenates were suppressed. Moreover, the in vivo studies
showed that carboxyfullerene antioxidant activity preserves
nigrostriatal dopaminergic system from iron-induced oxidative
damage.
Another study investigated the antioxidant potential of carbox-
yfullerene for cells of immune system, with protection of inactive
human peripheral blood mononuclear cells (PBMCs) from apo-
ptosis induced by TNF-a plus cycloheximide or 2-deoxy-d-ribose
(dRib) agents [229]. In summary, along with other biological
applications, fullerenes can be used as powerful antioxidants
and are more active than currently used compounds like vitamin
E.
Yao et al. [230] investigated the radical scavenging kinetics of
four fullerene polymeric systems including C60-PAA-C60, PAAC60,
PDMA-C60 and PEO-b-PAA-C60. The radical scavenging process of
these fullerene polymeric systems contained two stage kinetic
trends which relates to unimers and micelles existing in aqueous
solution of fullerene polymeric system. Moreover, they reported
that in free radical scavenging process micelles and unimers react
with radicals. Increasing of the number of fullerenes in larger
micellar cores results in faster reactions of radicals. In fact, they
concluded that nanostructure has an effect on antioxidant activity
of fullerene polymers [230].
Cancer treatment and photodynamic therapy
As mentioned above, fullerenes have been known as a radical
scavenger and antioxidant agents, but, paradoxically, they can
act also as oxidants. In fact they are able to promote the produc-
tion of ROS within cells and consequently can stimulate develop-
ment of oxidative stress in some circumstances [231,232].
Prior to the hypothesis reported by Andrievsky et al. in 2009
[233], it was assumed that covalent bonds of fullerene react with
ROS and form covalent bonds, however this assumption made
difficult to explain how fullerenes produce ROS during photody-
namic therapy [234]. Andrievsky et al. reported that hydrated
fullerenes can inactive ROS by the ordered ‘water coat’ rather than
covalently scavenging free radicals, considering that the ordered
‘water coat’ can trap two hydroxyl radicals for enough time to react
with each other and generate less reactive hydrogen peroxide
species [233].
One of the cancer treatment strategies using fullerenes is light-
based therapies such as photodynamic therapy and photothermal
therapy (PTT) [235,236]. Photodynamic therapy is a non-invasive
and nonsurgical treatment for some type of tumors and some of
non-malignant diseases. Photodynamic is a photochemical meth-
od that uses photosensitizing agents (photosensitizer [PS]) and
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FIGURE 13
Molecular structure of PS porphyrin-C60 dyad.
FIGURE 12













wlight irradiation to produce reactive oxygen species in tumor
tissue, to induce damage and apoptosis. The schematic of this
process is shown in Fig. 12 [16,234,237].
Fullerenes can be applied as possible PS for photodynamic
therapy [234,238]. Functionalization of the fullerene molecule
can promote its capability to produce reactive species which
can mediate PDT in medicinal applications [234]. When C60 is
irradiated with visible light, it can be excited from S0 ground state
to a short lived state, S1, excited state. S1 quickly decay to lower
lying triplet state T1 which has a long life time (50–100 ms; Eq. (1)).
C60þ hn ! 1C60 ! 3C60 þ 3O2 ! C60þ 1O2 (1)
In the presence of dissolved oxygen (3O2), existing as a triplet in
its ground state, fullerene T1 is quenched to produce singlet
oxygen (1O2). So, pristine and functionalized fullerenes are able
to catalyze ROS production upon light irradiation. In vitro studies
for the evaluation of fullerene in photodynamic therapeutic appli-
cations were implemented in 1990s. Tokuyama et al. proved the
phototoxic effect of fullerene functionalized with carboxylic acid
on human cervical carcinoma cells [239]. The toxicity and super-
oxide production ability of water-soluble polyethylene glycol
fullerene derivative under visible light was demonstrated by Naka-
jima et al. [240]. Burlaka et al. [241] also demonstrated the photo-
xicity of pristine and functionalized fullerene in carcinoma cells by
ROS generation: the phototoxicity of dendritic C60 monoadduct
and TMA-C60 derivatives was investigated on Jurkat cells (T-lym-
phocytes) under UV irradiation, and the results showed that tris-
malonic acid derivative is more phototoxic than dendritic one in
killing Jurkat cells [242]. Ji et al. also investigated the biodistribu-
tion and tumor uptake of C60(OH)x in five kinds of mouse bearing
tumors demonstrating the utility of this derivative as photosensi-
tizer in photodynamic therapy of some tumors [205].
One of the most soluble fullerene copolymers, C60-N
vinylpyrrolidone, under visible light irradiation demonstrated
its potential as a photodynamic therapy agent [243]. Mroz et al.
studied the photodynamic activity of cationic and hydrophilic
functionalized fullerene towards mouse cancer cell lines [235].
They showed that the fulleropyrrolidinium salt could be used as an
efficient photosensitizer for killing cancer cell by inducing apo-
ptosis under illumination, with the already mentioned mecha-
nism. The phototoxic activity of porphyrin-C60 dyad (p-C60, itsschematic shown in Fig. 13) on Hep-2 human larynx-carcinoma
cells was assessed by Alvarez et al. [244]. The dyad has the potential
to form photoinduced charge-separated state and can act as a
photodynamic agent for cell inactivation. The mechanism by which
P-C60 induced apoptosis was caspase-3-dependent [244]. Zhao et al.
evaluated the phototoxicity of four different forms of fullerene
prepared by solvent exchange and using dispersant agent: the results
showed all four preparation have potential in photogeneration of
singlet oxygen and superoxide [180]. While in the dark no cytotox-
icity was observed, the main photoinduced cytotoxic activity was
due to singlet oxygen rather than superoxides [39]. The photody-
namic activity of fullerene towards HeLa cells has been investigated,
the combination of cucurbit[8]uril–fullerene complex and light
resulted in HeLa cells death, due to damage of membrane proteins
and phospholipids [245]. C60-PEG-Gd, which is prepared by mixing
gadolinium acetate solution with C60-PEG-DTPA, is a photosensitiz-
er which have been developed by Liu et al. [246], the toxic effects and
anti-tumor activity were evaluated by intravenous injection to mice
bearing tumor and after light irradiation it resulted in photodynam-
ic activity, irradiation time dependent.
In vitro experiments to evaluate the photodynamic therapeutic
applications of pullulan-fullerene derivative showed that it can
prevent the growth of HepG2 heptoma cells, while experiments
via intravenous injection exhibited stronger antitumor activity in
comparison with C60-PEG conjugate or saline [247]. Nobusawa
et al. developed pH sensitive 6-amino-g-cyclodextrin (ACD) as
carrier for C60 in order to release it for photodynamic activities
on acidic surface of cancer cells [248]. In vitro experiments showed
that ACD/C60 can be taken up into cancer cells. In the same year,
Hu et al. [249] synthesized a fullerene derivative using L-phenylal-
anine, L-arginine and folic acid in order to alter fullerene limited
solubility which leads to lower singlet production in photody-
namic therapy. The results demonstrated that the uptake of this
fullerene derivative in HeLa cells was higher than in normal cells
and the subsequent photoirradiation raises 1O2=O2
 generation
and induces cell apoptosis [249].
A newer approach for cancer treatment implies the combination
of C60 derivatives with other molecules. For instance Shi et al.
coupled iron oxide nanoparticles with C60, and functionalized it
with PEG, in order to improve its solubility [250]. This nanocom-
posite can be used for photodynamic therapy and MRI and also as a471
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eviewdrug delivery system if in combination an antitumor drug, hema-
toporphyrin monomethyl ether (HMME). In this case, the photo-
dynamic effect is higher than for free HMME. Also a complex of
C60 with g-cyclodextrin polymer has been synthesized in order to
improve phototoxicity of fullerene and make it more water-solu-
ble, with higher efficacy in producing singlet oxygen and killing
cancer cells under UV irradiation [251].
Later, a drug delivery system including C60-PEI, a fullerene
derivative loaded with doxorubicin (DOX, an anticancer drug)
was developed to combine chemo- and photodynamic therapy for
cancer treatment. The DOX release in this system is greatly de-
pendent on pH values and in acidic condition (as in tumor cells)
DOX was released with higher speed, with good inhibition of B16-
F10 cells growth in vitro and, in in vivo experiment, good tumor
suppression in murine melanoma cancer. Moreover, the side
effects were lower that free DOX. The results gave credit to C60-
PEI-DOX to be used as a nanomedicine for cancer treatment [252].
In other studies, C60-DOX combination was developed as antitu-
mor complex [253,254]. At first Prylutskyy et al. examined the
structural and physiochemical properties of fullerene-DOX com-
plex for tumor inhibition [254], and in a later study [253], they
compared antitumor activity of fullerene-DOX combination with
pristine fullerene and DOX themselves, used separately, in the
treatment of Lewis lung carcinoma in male mice. Based on their
results, combination of fullerene and DOX was more efficient in
inhibiting the tumor growth in in vivo models and it could be used
as an effective approach in antitumor therapy [253].
Additionally, fullerene-DOX complex was investigated for its
cytotoxic activity in tumor therapy [255], and the results revealed
that presence of fullerene improved the cytotoxic effect of DOX
towards tumor cells by increasing hydrogen peroxide cellular
production although in in vivo model the effect was more notice-
able than that in in vitro experiments [255]. These results are
somewhat in contrast with a foregone study that has been carried
out in 2005 [256], which demonstrated that fullerenol has modu-
lating effects on three antitumor drugs (DOX, cisplatin, and taxol)
when administered in combination. Further researches and inves-
tigations on C60-DOX complex have been developed and recently
Prylutskyy et al. proved that C60-DOX hetero-complexation is
responsible for their synergy in physiological media [257].
The conjugation of Hoechst 33258-hyaluronate fullerene
(Ho-HF) was examined to evaluate its antitumor activity against
HCT-116 cells via photodynamic treatment in vitro, exploiting
Ho-HF conjugation to improve the PDT efficacy of fullerene
[258]. Self-assembled microspheres containing fullerene-phenylal-
anine-poly lactic acid (C60-Phe-PLA) were synthesized in order to
carry Mitroxantrone (MTX), an antitumor drug. The combination
of sustained release of MTX and high photodynamic activity of
C60-Phe-PLA demonstrated the potential of effective cancer treat-
ment along with minimum side effects on normal tissues [259]. In
a recent study, a chitosan oligosaccharide was grafted on fullerene
in order to generate endogenous ROS in mitochondria in human
malignant melanoma (A375) cells and results demonstrated that
low dose of fullerene can encourage the generation of endoge-
nous ROS [260].
The influence of fullerene nanoparticles on effectiveness of
the microwave heating for cancer treatment has been reported,
in this study the combination of microwave heating and C60472encapsulated in Pluronic F127-chitosan nanoparticles, a highly
water soluble fullerene derivative which can be taken up by the
cells and the improve the outcomes of the microwave hyperther-
mia for killing cancerous cells [261]. Various fullerene derivatives
separately or in conjugation with other materials were utilized to
assess their efficacy in photodynamic treatment of cancers: the
overall results showed that fullerenes are promising nanoparticles
be used in different cancer therapeutic approaches. Moreover, the
combination with a number of antitumor drugs suggested that
these constructs could be a promising approach in cancer therapy,
even though further developments in this field requires more
advanced investigations.
Anti HIV activity of fullerenes
HIV protease is the basic enzyme which assurances virus survival
and is specific for HIV proteins, so it is one of the main targets for
antiviral treatments. The active site of HIV protease is a semi-
opened hydrophobic ellipsoid, with Asp-25 and Asp-125 standing
out on the surface of the cavity and catalyzing the protease
function on the scissile peptide bond of the substrate. The diame-
ter of cavity is 10 A˚, close to the diameter of C60 cage [39,262]. The
antiviral activity of fullerene derivatives is mainly related to its
molecular structure. Friedman et al. [262] reported that HIV pro-
tease can be inhibited introducing a fullerene molecule into the
catalytic cavity [262,263]. Embedding C60 sphere in the center of
cavity allows Van der Waals interactions. The evaluation of anti-
viral activity of amphiliphilic fullerene bisadducts prepared by
Prato and coworkers showed different inhibition of HIV-1 [264].
They also reported that this inhibitory activity in fullerene deri-
vatives is strongly related to functionalization sites. Marchesan
et al. synthesized bis-fulleropyrrolidium salts (Fig. 14) in order to
evaluate their inhibitory activity against HIV-1 and HIV-2 [265],













wfinding that the position of the side chains influences the antiviral
activity, and trans fullerene bisadducts are more active than the cis
one. Also Kotelnikova et al. reported that amino acid derivatives of
fullerene are able to inhibit HIV [266].
Amino acid fullerene derivatives (ADFs) carrying bivalent metal
ions penetrate through lipid bilayer of liposomes, insert to hydro-
phobic domains of proteins and therefore change the function of
membrane bound enzymes. Cationic, anionic and amino acid
derivatives of fullerene have been tested for antiviral activity by
Mashino et al. and their results demonstrated that amino acid
derivatives are the most active derivatives. The authors also com-
pared HIV inhibition activity of fullerene derivatives with nevira-
pine (a clinical used HIV inhibitor) and they found that fullerene
derivative is even more effective than nevirapine itself [267]. The
anti-HIV activity against both HIV-1 and HIV-2 of fullerene
derivatives of multiple carboxylic acid moieties was also evaluat-
ed by Troshin et al. [268]. They reported a fascinating approach
using fullerene-sugar hybrid for photodegradation of HIV-1 pro-
tease. The role of the sugar was to promote the interactions
between hybrid and HIV-1 protease via hydrogen bonding.
UV/vis irradiation of hybrid-HIV-1P complex led to the virus
degradation, which is attributed to generation of ROS by fullerene
[268]. The enzymatic inhibition activity of TMA-C60 was also
investigated and proved by Yang et al. [269] in 2007; however,
this inhibition probably did not have any relation to ROS
production.
In summary, fullerene derivatives can complex and inhibit HIV
protease based upon their structure, being able to bind in the
cavity regions of HIV protease and inhibit virus replication signifi-
cantly [270,271], and also on their ROS generation activity.
Fullerene in drug delivery
Among the conventional methods for delivering drugs, oral and
injection administration are the most used. In addition to these
methods, there are some alternative approaches including pulmo-
nary, transdermal, transmucosal, ocular administration and im-
plantation [272]. By using drug delivery systems including
nanoparticle carriers, the pharmacokinetics can be dramatically
improved [273]. Transferring bioactive elements like proteins,
DNAs, and also various small molecules through the membrane
into cells (cellular delivery) drew considerable attention due to its
essential role in medicine and drug delivery [274,275], and the
possibility to reach the cell nucleus is even more limited by
various barriers and really challenging [276]. Numerous nano-
particles can be used for targeted drug delivery and controlled
release due to their biocompatibility and incredible characteris-
tics, and fullerene exhibits a great potential in drug delivery
systems [38,276,277].
Geometry, size and surface of fullerene cage seem to be appro-
priate for this application, considering its diameter in the range of
1 nm, approximately half of the average diameter of DNA helix
[272]. Despite the hydrophobicity of fullerene cage, as already
mentioned, it can be functionalized by hydrophilic moieties
achieving water-solubility and used as drug carrier for bio-active
molecules in biological environment. The first attempt in this field
has been accomplished by Nakamura et al., who synthesized two
handed tetraminofullerenes which bound duplex DNA [278],
therefore these DNA-fullerene nanoparticles are capable to enterCOS-1 cells. Foley et al. demonstrated that a fullerene derivative,
C61(COOH)2, can cross the cell membrane and also localize into
mitochondria, therefore it can be used in organelle-targeted drug
delivery [133,277]. A fullerene derivative bearing two diamino
side-chains was used for gene delivery to mammalian cells, enter-
ing the cell by endocytosis [279]. Rouse et al. proved that fullerene-
based peptides are able to penetrate intact skin and, accordingly,
can be applied in drug delivery [280], moreover the authors also
found that mechanical flexion can increase the penetration rate of
the nanoparticles into the dermis.
The main positive point in fullerene-based drug delivery sys-
tems is their ability to carry multiple drug payloads like taxol plus
other chemotherapeutic drugs. This approach is really beneficial in
cancer treatment, since cancer cells are easily drug-resistant and
effective treatment often needs combination of more than one
type of drug to overcome the resistance mechanism [281].
A drug delivery system containing fullerene and paclitaxel,
ranging about 120–145 nm, was proposed by Zakharian et al.
[282] in order to perform aerosol liposome delivery of paclitaxel
for lung cancer treatment. Half-life of paclitaxel in bovine serum
was 80 min and the paclitaxel release took place by enzymatic
hydrolysis.
Buckysomes, the spherical nanostructure made of amphiphi-
lic fullerenes which present many hydrophobic regions, can
embed hydrophobic molecules like paclitaxel, a very hydropho-
bic anticancer drug, inside its hydrophobic pockets [283]. This
spherical nanocarrier has been synthesized in aqueous environ-
ment and presents a diameter in order of 100–200 nm. Bucky-
somes were compared to abraxane, which also have been
used for delivering paclitaxel to suppress MCF-7 breast cancer
cells. The results demonstrated that paclitaxel embedded bucky-
somes can deliver higher amount of paclitaxel than abraxane
[283,284].
A new class of water soluble fullerene-based transfecting agents
has been synthesized using Hirsch–Bingel chemistry, and its ability
in gene delivery has been evaluated: these derivatives can complex
DNA, deliver it into cells and evoke gene expression [285].
Doxorubicin, as mentioned previously, is a precious antican-
cer drug but induces acute and chronic side effects. In order to
mitigate its side effects one strategy is the use of drug delivery
systems [10]. Fullerenes, due to their antioxidant and radical
scavenging activity, have the potential to be conjugated with
DOX and to mitigate the DOX side effects trigger by ROS. The
challenge in this approach is that DOX is a water soluble while
fullerene is hydrophobic, so Sun et al. used ethylene glycol
spacers for conjugating methano-C60 with DOX, improving
the water solubility of the vector [286]. In a similar attempt
fullerenols were conjugated to doxorubicin through a carbamate
linker, in order to promote an efficient delivery [287]. This
conjugation repressed the cancer cell proliferation in vitro, by
blocking G2-M cell cycle, causing apoptosis. In addition, the
fullerenol–doxorubicin conjugate exhibited high antitumor ac-
tivity in vivo in a murine tumor model, without causing systemic
toxicity like free DOX [287].
Recently, Prylutskyy et al. [257] have proven that fullerene acts
as an interceptor for DOX and the hetero-complex of C60-DOX
performs as a nano-carrier for delivering doxorubicin to target
cells. The attractive point is that the conclusion derived from these473











eviewexperiments can be generalized to other aromatic drugs like acty-
nomycine D, mitoxantrone and topotecan [257].
An ‘on–off’ drug delivery system for cancer treatment has been
developed by conjugation of DOX and fullerene (C60) following by
attachment of the hydrophilic shell (distearoyl-sn-glycero-3-phos-
phoethanolamine-PEG-CNGRCK2HK3HK11, DSPE-PEG-NGR) to
outer surface of the conjugation. This drug delivery system has
strong stability in physiological solutions even with pH around 5.5
in the ‘off’ state, in contrast, in the ‘on’ state the generation of ROS
by C60 results in the breaking of the ROS-sensitive linker which
enables the exploding release of DOX. In this innovative drug
delivery system, the combination of photodynamic therapy and
chemotherapy could be applied against tumor cells [288].
Furthermore, fullerenes were conjugated to other species like
nitroxide radicals to preserve normal tissue and cells against
chemotherapy [37], they also can be conjugated to metals com-
plexes, such as cisplatin, which is widely used for cancer chemo-
therapy [287,289]. Also in this case the anticancer activity against
Lewis lung carcinoma cells of the conjugate was more efficient
than the free drug [287].
In line with fullerene drug delivery applications, porphyrin
adducts of cyclohexyl-fullerene were prepared for targeted delivery
of Mg2+ to the heart muscles [290], which resulted in 80% recovery
of tissue hypoxia symptoms less than 24 hours after a single
injection. Release of Mg2+ by nanoparticles caused to stimulate
ATP overproduction in oxygen depleted cells. Since these smart
nanoparticles release Mg2+ cations just in reaction to the metabolic
acidic shift, the positive changes in heart cell energy metabolism
can help the treatment and preventing local myocardial hypoxic
disorders and protect heart muscles in different hypoxia-caused
clinical situations [290].
Fullerene also have been used in delivery of bioactive molecules
like warfarin, a coumarin anticoagulant drug. Conjugation of
warfarin to fullerene can alter its biological profile and prevent
variation of its concentration in the blood [58,291]. Erythropoie-
tin (EPO), a hormone mainly produced by kidneys, also can be
linked to fullerenes and carbon nanotubes. EPO usually is admin-
istered through intravenous injection, although its biological
activity is reduced abruptly in this route. Nanoparticulate system
can be used for effective administration of EPO: for example EPO
was absorbed on porous materials containing fullerene and its
bioavailability was intensely enhanced compared to conventional
administration [58,292].
The highly water-soluble and non-cytotoxic fullerene deriva-
tive, malonodiserinolamide C60 (C60-Ser), was investigated as
delivery system. The internalization of PF-633 fluorophore conju-
gated with C60-Ser (C60-SerPF) within living cancer cells was ob-
served. In addition, in vivo experiments in mouse, bearing liver
tumor, demonstrated that C60-SerPF permeated through the vas-
culature of the tumor and it was detected in many tissues [293].
In another study, PEI-derivatized C60 was prepared by cationic
polymerization of aziridine on the surface of C60-NH2. Then, PEI-
C60 was decorated with folic acid (FA) via amide linker, and
docetaxel (DTX) was conjugated to C60-PEI-FA resulting in a
complex drug delivery system [228], able to cross cell membranes
and to cause apoptosis in tumor cells and exhibiting higher
antitumor efficacy than free DXT, without toxic effects on
normal tissues [294]. Recently, another fullerene-based drug474delivery system has been prepared via grafting hyaluronic acid
(HA) onto fullerene and combining this with transferrin (Tf),
which has antitumor efficacy and also can be used in photody-
namic therapy [295]. Artesunate, an iron-dependent antimalarial
drug, which is cytotoxic against tumor cells, was loaded into
HA-C60-Tf with a high loading efficiency. The in vitro and in vivo
evaluation of this system demonstrated its high antitumor effi-
cacy [295].
Fullerenes in biosensors
A biosensor is an analytical device which can sense the presence
and determine the amount of biomolecules, enzymes, microor-
ganism, organelles, antibodies and receptors by combining a
biological sensing element or a recognition site with a transducer
[296,297]. The recognition site responds to the presence of the
biomolecules and the transducer converts this to signals which are
measureable [298].
Fullerenes can be used as mediator between recognition site and
biosensor electrode, amplifying the electron transfer rate created
by biochemical reactions of analyte and biological component in
recognition site [298,299]. Considering that an efficient mediator
should be hydrophilic and possess functional groups, which help
it to conjugate the biomolecules in order to promote electron
transfer at the reaction site, pristine fullerene does not seem to be
the most advantageous mediator being hydrophobic and insoluble
in polar media. However, fullerene derivatives can be effective
material for using in biosensors [36,298]. Intensive research ac-
complished on C60 derivatives demonstrated that functionaliza-
tion imparts characteristics which improve the efficacy in
biosensor applications [299]. Among the other groups, carboxylic
acid, amine and hydroxyl groups are beneficial in allowing the
interactions between fullerenes with biomolecules [300]. The C60-
containing supported bilayer lipid membranes (s-BLMs) as molec-
ular device have been investigated by Tien at al. [301] in 1997. The
results showed that C60 inserted in BLM is an efficient electron
mediator which can be used in biosensors. Following this investi-
gation, Szyman´ska et al. used this method in an electrochemical
sensor for the detection of neutral odorant and demonstrated that
functionalized fullerene facilitates charge transmission [302]. Ful-
lerene also have been used in glucose biosensing and overcome
some limitations which exist in glucose determination [303]. The
first attempt in this field was done in 2000 and various amounts of
fullerene from 0.6 to 1.7 mm were immobilized to amperometric
biosensor against glucose oxide enzyme. The results showed that,
with the increasing of the fullerene amount, the sensitivity of
biosensor also improved [304]. Later, a fullerene-cryptand-22
coated sensor was applied for sensing gluconic acid which is
produced via glucose oxidation. The experiments demonstrated
that this biosensor is selective to glucose and no interferences
caused by biological samples were observed [305]. Furthermore,
fullerene-cryptand-22 was used to coat piezoelectric quartz crystals
along with immobilized C60-urease membrane for sensing ammo-
nium ions deriving from the catalytic hydrolysis of urea by urease
[306]. Similar to this study, the C60-coated piezoelectric quartz
crystal sensor with immobilized C60-lipase silicate plates was
applied in order to detect optical isomer of amino acid esters.
The synthesized sensor was capable to distinguish between L- and
D-amino acid esters [307].
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FIGURE 15
Schematic of functionalized fullerene containing free amino group and N-













wZhilei et al., with an inventive approach, developed a glucose
biosensor exploiting fullerene along with ferrocene (Fc), chitosan
(CS) and ionic liquid (IL) [308]. The efficacy of this biosensor was
evaluated by chronoamperometry, cyclic voltammetry and imped-
ance spectroscopy. The fast response of this biosensor and the
minimum value of Michaelis–Menten Constant (km) among other
glucose biosensors demonstrated the high sensitivity and great
performance of this biosensor. In this fullerene supports the
oxidation of glucose molecules and stimulates the electrochemical
reaction that results in the most applicable response in ampero-
metric biosensors [308]. In 2012, novel Pd@Cys-C60 nanoparticles
were developed via in situ spontaneous reduction process, which
was exploited for sensing glucose in glucose solution and human
serum. The results showed that this biosensor has a linear range
from 2.5 mM to 1 mM and also no interferences from other biomo-
lecules were reported [309]. A carboxyfullerene bisadduct,
C60[C(COOH)2]2, possesses peroxide-like catalytic activity and
can catalyze the reaction of peroxidase substrate 3,30,5,50 tetra-
methylbenzidine (TMB) in the presence of H2O2. Therefore,
C60[C(COOH)2]2/glucose oxidase (GOx)/TMB system was designed
to be a colorimetric sensor for glucose, which showed a detection
range of 1.0–40 mM. In addition, this highly sensitive colorimetric
biosensor can be exploited for quantitative measurement of glu-
cose in human serum [310]. In similar studies, functionalized
fullerene was used as a mediator in glucose biosensors, exhibiting
a convenient electron transfer between glucose oxide and glassy
carbon [311,312]. Also Saeedfar et al. synthesized a urea biosensor
using carboxyfullerene derivatives [313]. This biosensor contained
fullerene–urea bioconjugate on an acrylic based hydrogen ion
sensitive membrane, and demonstrated acceptable sensitiveness
and response time.
In a recent study, a novel nanocomposite consisting of 3-amino-
capto-1,2,4-triazole functionalized fullerene-C60 coated by gold
nanoparticles dispersed on a glassy nanostructured carbon elec-
trode has been developed in order to investigate non-enzymatic
sensing properties. This nanocomposite revealed excellent cata-
lytic activity that is promising for application in glucose sensors
with a really low detection limit [314]. However, considering the
attractive properties of fullerenes, extensive investigations are
needed to better exploit fullerene derivatives in the fabrication
of biosensors, which remains an important field of application.
Other biomedical applications
Fullerene for osteoporosis treatment
Osteoporosis is a disease which makes bones brittle and prone to
fracture even with mild stresses. This happens when the bone
density decreases and the bone tissue has become weaker and
caused fracture in hip, spine and wrist commonly. It is well known
that hydrophilic bisphosphonate groups have affinity towards the
prominent bone mineral, hydroxyapatite, which is applicable in
osteoporosis and other bone related diseases [39]. Fullerene was
coupled to bisphosphonate to prepare a tissue-vectored com-
pound, namely C60(OH)16AMBP. The in vitro experiments demon-
strated that this compound possesses good affinity for
hydroxyapatite and reduces its mineralization by 50% at 1 mM
concentration [315]. Also C60(OH)30 reduces mineralization of
hydroxyapatite (28% crystal growth rate) and exhibits affinity
for hydroxyapatite [315]. Some studies reported that the reactiveoxygen species contribute in osteoclast differentiation begins with
RANK-RANKL signals [316–318]. Therefore, controlling ROS can
help in the treatment of osteoclast hyper-resorption on osteoar-
thritis. It has been proved that, in rat model, fullerene can reduce
joint destruction and suppress bone resorption caused by osteo-
clasts [318]. Fullerenols also can stimulate osteogenesis in bone
marrow, via eliminating ROS in models which experience oxida-
tive stress caused by dexamethasone [319,320].
Antimicrobial activity of fullerenes
In 1990s, fullerenes have been evaluated for their antimicrobial
activity and promising results on suppressive effects on bacteria
including Bacillus subtilis, Candida albicans and E. coli were
obtained [321,322]. The study on carboxyfullerene revealed that
it can be exploited as an antimicrobial agent to suppress group A
streptococcus infection [323]. The antimicrobial activity of car-
boxyfullerene was examined against Streptococcus pyogenes infec-
tion. In vitro experiments showed that this derivative can suppress
growth of S. pyogenes and its administration to mice protects the
33% of them from death [323]. A fullerene peptide has been
fabricated via solid-phase peptide synthesis from functionalized
fullerene containing free amino group and N-Fmoc-L-glutamic
acid a-tert-butyl ester (Fig. 15) and its activity against bacteria,
Staphylococcus aureus and E. coli was tested [324].
Tsao et al. in 2002 investigated the antimicrobial effect of
carboxyfullerene on twenty bacteria strains [325]. The results
revealed the role of this compound on inhibiting Gram-positive
bacteria, while it had no effect on Gram-negative bacteria [325].
Photodynamic inactivation is an emerging antimicrobial ap-
proach that fullerene derivatives, especially water-soluble cationic
ones, can facilitate upon irradiation, and in this case the com-
pounds exhibit their activity both against Gram-positive and
Gram negative bacteria [326].
In another study, a colloidal water-solution of C60was prepared
and the bacterial response to this nC60 preparation was examined
[145]. Low concentration of nC60 inhibited the growth of Gram-
positive and Gram-negative bacteria in various conditions [145].
Following this study, Lyon et al. investigated the antibacterial
activity of nC60 and the influence of the aggregates morphology
on the antibacterial activity using B. subtilis [327]. Therefore, they
papered fullerene water suspensions with four different strategies.
The results displayed that the smaller fullerene aggregates, the
higher antibacterial activity, this phenomenon could be related475











eviewto the surface area that in suspensions with smaller fullerene
aggregates is greater and provides higher antibacterial activity
[327].
The sub-lethal concentrations of colloidal aggregates of C60 in
water also can induce some adaptions in the Gram-negative Pseu-
domonas putida and Gram-positive B subtilis bacteria including
modification of membrane lipid composition, membrane fluidity
and phase transition temperature [328].
The genotoxicity of fullerene on bacteria has been investigated
in two distinct studies [206,329]. In the first fullerene did not
demonstrate any genetic damage in Salmonella typhimurium and E.
coli [206]. In contrast with this report, the latter study demonstrat-
ed DNA-damaging potential of fullerene towards B. subtilis by Rec-
assay and umu test. Therefore, these results are not conclusive and
DNA damage of fullerene was not caused by covalent DNA adduct
formation, but there is an indirect mechanism which needs further
investigations [329].
Fullerenes as neuroprotective agent
Hyper-production of reactive oxygen and nitric oxide species, due
to over excitation of glutamic acid receptors, can cause cell death
resulting in chronic neurodegenerative diseases like Alzheimer’s
and Parkinson [39]. Neuroprotective activity of fullerene deriva-
tives is similar to their radical scavenging activity. As mentioned
above, fullerene and fullerenols have outstanding antioxidant
activity. Their ability to reduce apoptosis in cortical neurons
and also to block glutamic acid receptors have been reported
[219,330]. Also the effectiveness of carboxyfullerenes in the treat-
ment of amyotrophic lateral sclerosis (ALS) has been studied [331].
Hexasulfobutyl fullerenes and TMA fullerenes also demonstrated
their ability to trap free radicals and play an efficient role in
neurodegenerative diseases treatment [67,332]. Zha et al. investi-
gated the correlation between fullerenes concentration and their
activity [333]. At low concentrations, fullerenols exhibit neuro-
protective effect and increase hippocampal neuronal viability,
while at high concentrations, opposite results were observed
and hippocampal neuronal viability was reduced, with conse-
quent apoptosis.
The experimental allergic encephalomyelitis (EAE) [334] has
been use as animal model to investigate the effect of fullerenes
in neuroprotection [335]. It has been reported that a water-soluble
fullerene derivative (ABS-75) bearing adamantyl units as NMDA
receptor antagonist can block axonal damage and decrease pro-
gression in a chronic and progressive EAE model [335]. The role of
fullerene in suppressing EAE suggests that the compound can be
used as therapeutic strategy in controlling human multiple scle-
rosis [271]. Based upon various studies, water-soluble derivatives
such as fullerenols and malonic acid fullerenes can react with
hydroxyl and superoxide free radicals and reduce neuronal degen-
eration related to ROS [219].
Fullerenes as MRI contrast agent for diagnosis
Magnetic resonance imaging is a technique, which uses gadolini-
um-based contrast agents. Fullerenes with their hallow cage can be
used for encapsulating gadolinium in order to address challenges
related to the use of Gd chelates for MRI [336], considering that
after injection, C60 distributes in tissues and relocates in selected
organs without detectable and acute toxicity [39]. Endohedral476fullerenes, which entrap metal atoms in the molecular cage with-
out releasing them even in vivo, are good candidates as contrast
agent both in magnetic resonance imaging and X-ray imaging
[38,39].
The first approach in using fullerene endohedrals in MRI was
reported by Wilson et al. [337]. Gd@C60[C(COOH)2]10 is water-
soluble and it is easily uptaken in the reticuloendothelial system
(RES). Later on Toth et al. also investigated the MRI applicability
of Gd@C60(OH)x [338]. They showed that, being water proton
relaxivities dependent on temperature, magnetic fields and also
pH, these gadofullerenes possess the potential of pH-sensitive
MRI contrast agent. Moreover Liu et al. investigated the poten-
tial of Gd3+-PEG-C60 in both of photodynamic therapy and
magnetic resonance imaging (MRI), the presence of Gd3+ con-
verts PEG-C60 to a photosensitizer with dual application in
diagnosis and treatment [246]. Shu et al. synthesized gadofuller-
ene MRI contrast agent starting from higher fullerenes, as
Gd@C82O6(OH)16(NHCH2CH2COOH)8, to evaluate its capability
in magnetic resonance imaging and also in this case it was
demonstrated that they have promising characteristics in this
field [339–341].
Fullerenes in cosmetics
Personal care and skin care products intricately intertwined with
chemical industries. The emergence of nanotechnology in cos-
metics triggered about 40 years ago with using liposomes in
moisturizing creams [342]. Fullerenes, thanks to their antioxidant
activity, are used in moisturizers [342]. For the first time, Inui et al.
investigated the clinical efficacy of fullerenes for treating acne
[343]. A fullerene-based gel was used in this study, decreasing the
inflammatory lesions. Fullerene derivatives were reported to ex-
hibit antioxidant activity and also anti-melanogenesis without
any detectable cytotoxicity [344], and so they also have been used
for anti-aging products. A water soluble fullerene complex con-
sisting of PVP and C60 has been proven for its cytoprotective
activity against oxidative stress and its ultraviolet absorption
proficiency. The PVP/C60 is able to prevent the inhibitory effect
of UVB on keratinocyte proliferation by its antioxidative effect
that suggest the PVP/C60 could be applied in cosmetic products
due its free radical scavenging and as a barrier repair agent for
promoting keratinocyte differentiation [345]. Despite these com-
mercials uses, fullerenes may cause undesirable side effects, since
application of fullerene in cosmetic products increase human
exposure [346] and much more has to be investigated about this
application.
An interesting role of fullerene nanomaterials which has been
examined by the researchers is stimulation of hair growth. In this
study a fullerene derivative has been developed and its role in
treatment of hair loss has been examined. The results of experi-
ments exhibited that in fullerene-treated mice the hair growth and
also the number of hair follicles have increased compared to mice
receiving only vehicle [347]. Production of reactive oxygen species
as a possible underlying reason for aging and hair loss can describe
the mechanism in which fullerene treats hair loss and increase the
number of hair follicles, in fact, fullerene as a free radical scavenger
is an attractive therapeutic option for treatment of diseases in-
volving reactive oxygen species [347]. The various applications of
fullerene derivatives in biomedicine are summarized in Table 1.
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TABLE 1
Fullerene derivatives and their various applications in biomedical engineering.
Fullerene derivatives Applications Refs
Fullerenol or fullerenol, C60(OH)12 Antioxidant and reducing apoptosis in cortical neurons cultures [219]
Carboxyfullerene, C63((COOH)2)3 Inhibiting neurodegeneration involved in ALS [331]
C60(ONO2)72 With antioxidant activity can prevent oxidant-induced pulmonary diseases [220]
Amino acid derivatives of fullerene Antiviral activity [267]
Hexa(sulfobutyl)fullerene,
[C60(CH2-CH2-CH2-CH2SO3Na)6;(FC4S)]
Antiproliferative agent in the arteriosclerosis and inhibition
of plasma lipid peroxidation
[222]
Fullerenol Non-invasive image-guided cancer therapy [348]
Fullerenol Tumor inhibitory activity [349]
bis-Fulleropyrrolidines Inhibitory activity against HIV [265]
Fullerenol Anti-metastatic activity, cancer treatment [287,350]
C60(Nd) nanoparticles Inducing autophagy in cancer cells and enhancing
chemotherapeutic killing of cancer cells
[351]
C60[>M(C3N6
+C3)2][>M(C3N6C3)2](I)10 Antimicrobial photodynamic inactivation [352]
tris-Malonic acid fullerenes Radical scavenging [332]
Dendrofullerene Antioxidant activity [224]




Porphyrin-C60 PDT cell inactivation [244]
C60-PEG-Gd Anti-tumor activity [246]
Pd@Cys-C60 nanoparticles Glucose biosensor [309]
Cucurbit[8]uril–fullerene Photodynamic therapy [245]
Gd@C60[C(COOH)2]10 MRI contrasts agent [337]
6-Amino-g-cyclodextrin (ACD)/C60 Photodynamic therapy [248]
Hexasulfobutyl fullerenes Treatment of neurodegenerative diseases via radical scavenging [332]
Fullerene-cryptand-22 Urea biosensor [306]
Carboxyfullerene Antimicrobial and antibacterial activity [323,325]
C60(OH)16AMBP Osteoporosis treatment [315]
C60[C(COOH)2]2/glucose oxidase (GOx)/TMB Glucose colorimetric biosensor [310]
Carboxyfullerene Targeted drug delivery [133,277]
Carboxyfullerene Urea biosensor [313]
Hoechst 33258–conjugated hyaluronated fullerene Photodynamic tumor therapy [258]
Fullerene-phenylalanine-poly lactic acid Drug carrier – photodynamic therapy [259]
Cystine C60 derivative Inhibiting apoptosis [226]
Amphiliphilic fullerene bisadducts Inhibiting HIV [264]
DNA-fullerene nanoparticles Carrying drug [133,279]
Porphyrin adducts of cyclohexyl fullerene-C60 Targeted delivery of paramagnetic Mg
2+ isotope [290]
Fullerenol Stimulate osteogenesis in bone marrow [319,320]
Fullerene containing free amino group and
N-Fmoc-L-glutamic acid a-tert-butyl ester
Antibacterial activity [324]
Malonodiserinolamide derivatized fullerene Drug delivery system [293]













wConclusion and future outlook
Fullerenes have become important molecules in different health-
related subjects during the last three decades. The biomedical
applications presented in this manuscript represent potential uses
of this class of carbon family, due to its extraordinary properties(see Table 1). As more applications of these nanomaterials become
available, the demand for different forms of fullerenes will in-
crease. For future works, functionalized fullerenes will consider-
ably change the face of biological applications, and the credits
go to the collaborative efforts of scientists who focus on both477











eviewchemistry and medicine. These collaborative efforts are critical for
introducing the most effective modifications on the carbon cage
for successful diagnosis and therapeutic outcomes in different
biomedical applications. Here, we have provided an overview of
the ever-expanding research on fullerenes in biomedical engineer-
ing applications ranging from drug delivery to noninvasive imag-
ing in the human body. These studies are mostly limited to in vitro
and in vivo researches and have not reached the final stages of
clinical trials yet. It is expected that, with the rapid technological
advancement in this field, this trend could change in the coming
years so that the unique features of fullerenes could be exploited in
clinical use. Although there are still major issues to overcome, the
use of fullerenes for biomedical engineering will certainly have a
bright future.
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